Delcath Systems reports preliminary 2025 revenue of $85.2 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 9, 2026 8:05 AM ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.
Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited)
Total fourth quarter and full year revenue expected to be approximately $20.7 million and $85.2 million, respectively HEPZATO KIT fourth quarter and full year revenue expected to be approximately $19.0 million and $78.8 million,... More